HMA therapy for patients with myelodysplastic syndrome could potentially activate a sleeping oncogene
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.
United States National University Of Singapore Singapore General Daniel Tenen Emily Henderson Cancer Science Institute Of Singapore
Source: news-medical.net